AstraZeneca entered a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing treatments for rare endocrine diseases, for a total consideration of up to $1.05 billion, including $800 million upfront plus an additional contingent payment of $250 million based on a specified regulatory milestone.   The proposed acquisition will bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline and expand on its bone metabolism franchise with the...